XELOX, as second-line therapy, was found to be as effective as the more commonly used FOLFOX treatment for patients whose cancer had already gotten worse on treatment with Camptosar® (irinotecan).
XELOX combines an oral drug Xeloda® (capecitabine) with Eloxatin® (oxaliplatin). FOLFOX uses an infusional schedule of 5FU and leucovorin.
Researchers randomly compared XELOX to FOLFOX4 to treat 627 patients with metastatic colorectal cancer. Patients had already received initial therapy with Camptosar and either had their cancer progress or were unable to tolerate the treatments. Although outcomes were similar for the two regimens, side effects differed.